Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Micki Hultquist_2024
AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo
Shots:  AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines  Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE)  The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024
VIEWPOINTS_David Domzalski_2024
Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement
Shots:  David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots  The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform  David believes the financing will be instrumental in the advancement of VYN201, into…
January 29, 2024
VIEWPOINTS_Thirusha Lane_2024
Breaking the Barriers of hATTR Treatment: Thirusha Lane Shares her Insightful Thoughts with PharmaShots
Shots:  Often, patient care focuses solely on therapeutics, but with rare diseases like hATTR amyloidosis, integrating holistic care for patients is crucial to ensure patients fully live their lives  In an enlightening conversation with PharmaShots, Thirusha Lane shares the highlights of the recommendations developed by the international panel of patient advocates and HCPs for people…
January 22, 2024
VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots
Shots:    Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL   Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024
VIEWPOINTS_Brian Quigley_2024
Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia
Shots:  Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots   The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio   During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
January 8, 2024
VIEWPOINTS_Justin Schreiber_2023
Justin Schreiber Discusses the Recently Launched D2C Telehealth Model for Hormone Therapy
Shots:   Justin Schreiber, Chairman, and CEO of, LifeMD, in an illuminating conversation with PharmaShots, discusses the recent partnership with ASCEND Therapeutics    LifeMD, a virtual primary care company, and ASCEND Therapeutics, a leading women's health pharmaceutical company, came together to bring an integrated direct-to-consumer telehealth model to enhance the way women receive care for their menopause…
December 21, 2023
VIEWPOINTS_Dr. Lotus Mallbris_2023
Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults
Shots:    Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease    While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…
December 19, 2023
Load more